Clinical Trials » Retinitis Pigmentosa
Valproic Acid for Autosomal Dominant Forms of RP
|
RECRUITING Description: In preclinical studies and limited clinical evaluations, valproic acid has shown the potential to slow the progress of vision loss from autosomal dominant forms of retinitis pigmentosa (RP). Valproic acid is a drug FDA approved for the treatment of seizure disorders. The National Neurovision Research Institute, the clinical trial support organization of the Foundation Fighting Blindness, is funding a three-year, 90-participant Phase II clinical trial at the Retina Foundation of the Southwest (Dallas) and the University of Utah (Salt Lake City) to evaluate the safety and efficacy of valproic acid. Participants must be at least 18 years of age and have a diagnosis of autosomal dominant retinitis pigmentosa. Participants will be randomized to receive either placebo or valproic acid. Trial Status: Recruiting participants. Articles on Valproic Acid: FDA-Approved Drug Moving into Clinical Trial for Treatment of RP Participants Recruited for Valproic Acid Clinical Trial Valproic Acid Clinical Trial FAQ — Includes Inclusion and Exclusion Criteria Partial List of Participation Criteria:
Kirsten Locke, R.N. This e-mail address is being protected from spambots. You need JavaScript enabled to view it (214) 363-3911 ext 114 Retina Foundation of the Southwest (Dallas, Texas) Kim Wegner, R.N. This e-mail address is being protected from spambots. You need JavaScript enabled to view it (801) 581-6265 University of Utah Dr. Barbara Jennings This e-mail address is being protected from spambots. You need JavaScript enabled to view it (901) 448-6445 University of Tennessee -- Hamilton Eye Institute (Memphis) Potyra Aroucha This e-mail address is being protected from spambots. You need JavaScript enabled to view it (305) 202-4731 University Of Miami, Miller School of Medicine Starting in June 2012 Catie Beattie, MS, CGC This e-mail address is being protected from spambots. You need JavaScript enabled to view it (503) 494-2363 Casey Eye Institute Oregon Health & Science University (Portland) Pam Titus, COT This e-mail address is being protected from spambots. You need JavaScript enabled to view it (734) 763-5874 Kellogg Eye Center University of Michigan (Ann Arbor) Additional Information: Valproic acid clinical trial listing on ClinicalTrials.gov |
